Literature DB >> 31790654

Is Mortality a Useful Primary End Point for Critical Care Trials?

Richard A Veldhoen1, Daniel Howes2, David M Maslove3.   

Abstract

Mortality has long been used as a primary end point for randomized controlled trials in critical care. Recently, a plurality of trials targeting mortality end points as their primary outcome has failed to detect a difference between study arms. While there are a number of reasons for the preponderance of such neutral trials, the use of mortality as an outcome is one important consideration. We explore some of the reasons why such trials may be biased toward a neutral result, as well as reasons to consider alternative end points that are better coupled to the expected therapeutic effect. We also discuss to what extent mortality as a binary outcome is patient-important in the ICU.
Copyright © 2019 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  critical care; mortality outcomes; neutral trials; patient-important outcomes; randomized controlled trials

Mesh:

Year:  2019        PMID: 31790654     DOI: 10.1016/j.chest.2019.11.019

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  3 in total

1.  On Baseball, Counterfactuals, and Measuring Care Delivery Performance at the Emergency Department-Intensive Care Unit Interface.

Authors:  Patrick G Lyons; Shannon M Fernando
Journal:  Ann Am Thorac Soc       Date:  2020-12

Review 2.  Critical Analysis of a Randomized Controlled Trial.

Authors:  Balkrishna D Nimavat; Kapil G Zirpe; Sushma K Gurav
Journal:  Indian J Crit Care Med       Date:  2020-09

Review 3.  Randomised clinical trials in critical care: past, present and future.

Authors:  Anders Granholm; Waleed Alhazzani; Lennie P G Derde; Derek C Angus; Fernando G Zampieri; Naomi E Hammond; Rob Mac Sweeney; Sheila N Myatra; Elie Azoulay; Kathryn Rowan; Paul J Young; Anders Perner; Morten Hylander Møller
Journal:  Intensive Care Med       Date:  2021-12-02       Impact factor: 41.787

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.